|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
|
|
|
|||||||||
|
|||||||||||
|
J Am Coll Cardiol, 2002; 39:1615-1622 © 2002 by the American College of Cardiology Foundation |
* Department of Cardiology, University of Heidelberg, Heidelberg, Germany
Manuscript received August 13, 2001; revised manuscript received February 20, 2002, accepted February 25, 2002.
* Reprint requests and correspondence: Dr. Markus Haass, Department of Cardiology, University of Heidelberg, Bergheimerstrasse 58, D-69115 Heidelberg, Germany.
markus_haass{at}med.uni-heidelberg.de
OBJECTIVES: This prospective study tested the impact of beta-blocker treatment on currently used risk predictors in congestive heart failure (CHF).
BACKGROUND: Given the survival benefit obtained by beta-blockade, risk stratification by factors established in the "pre–beta-blocker era" may be questioned.
METHODS: The study included 408 patients who had CHF with left ventricular ejection fraction (LVEF) <45%, all treated with an angiotensin-converting enzyme inhibitor or angiotensin type 1 receptor antagonist, who were classified into those receiving a beta-blocker (n = 165) and those who were not (n = 243). In all patients, LVEF, peak oxygen consumption (peakVO2), plasma norepinephrine (NE) and N-terminal pro-brain natriuretic peptide (NT-proBNP) levels were determined.
RESULTS: Although the New York Heart Association functional class (2.2 ± 0.7 vs. 2.3 ± 0.7), peakVO2 (14.4 ± 5.2 ml/min per kg vs. 14.4 ± 5.5 ml/min per kg) and NT-proBNP (337 ± 360 pmol/l vs. 434 ± 538 pmol/l) were similar in the groups with and without beta-blocker treatment, the group with beta-blocker treatment had a lower heart rate (68 ± 30 beats/min vs. 76 ± 30 beats/min), lower NE (1.7 ± 1.2 nmol/l vs. 2.5 ± 2.2 nmol/l) and higher LVEF (24 ± 10% vs. 21 ± 9%; all p < 0.05). Within one year, 34% of patients without beta-blocker treatment, but only 16% of those with beta-blocker treatment (p < 0.001), reached the combined end point, defined as hospital admission due to worsening CHF and/or cardiac death. A beneficial effect of beta-blocker treatment was most obvious in the advanced stages of CHF, because the end-point rates were markedly lower (all p < 0.05) in the group with beta-blocker treatment versus the group without it, as characterized by peakVO2 <10 ml/min per kg (26% vs. 64%), LVEF 
20% (25% vs. 45%), NE >2.24 nmol/l (18% vs. 40%) and NT-proBNP >364 pmol/l (27% vs. 45%), although patients with beta-blocker treatment received only 37 ± 21% of the maximal recommended beta-blocker dosages.
CONCLUSIONS: The prognostic value of variables used for risk stratification of patients with CHF is markedly influenced by beta-blocker treatment. Therefore, in the beta-blocker era, a re-evaluation of the selection criteria for heart transplantation is warranted.
| ||||||||||||||||||
This article has been cited by other articles:
|
|
 |
|
  M. Rosenberg, C. Zugck, M. Nelles, C. Juenger, D. Frank, A. Remppis, E. Giannitsis, H. A. Katus, and N. Frey Osteopontin, a New Prognostic Biomarker in Patients With Chronic Heart Failure Circ Heart Fail, May 1, 2008; 1(1): 43 - 49. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. E. F. Daubeney, A. W. Nugent, P. Chondros, J. B. Carlin, S. D. Colan, M. Cheung, A. M. Davis, C.W. Chow, R. G. Weintraub, and on behalf of the National Australian Childhood Car Clinical Features and Outcomes of Childhood Dilated Cardiomyopathy: Results From a National Population-Based Study Circulation, December 12, 2006; 114(24): 2671 - 2678. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Passantino, R. Lagioia, F. Mastropasqua, and D. Scrutinio Short-Term Change in Distance Walked in 6 Min Is an Indicator of Outcome in Patients With Chronic Heart Failure in Clinical Practice J. Am. Coll. Cardiol., July 4, 2006; 48(1): 99 - 105. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Davis, A. M. Richards, M. G. Nicholls, T. G. Yandle, C. M. Frampton, and R. W. Troughton Introduction of Metoprolol Increases Plasma B-Type Cardiac Natriuretic Peptides in Mild, Stable Heart Failure Circulation, February 21, 2006; 113(7): 977 - 985. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Cohen-Solal, F. Rouzet, A. Berdeaux, D. Le Guludec, E. Abergel, A. Syrota, and P. Merlet Effects of Carvedilol on Myocardial Sympathetic Innervation in Patients with Chronic Heart Failure J. Nucl. Med., November 1, 2005; 46(11): 1796 - 1803. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. O. O'Neill, J. B. Young, C. E. Pothier, and M. S. Lauer Peak Oxygen Consumption as a Predictor of Death in Patients With Heart Failure Receiving {beta}-Blockers Circulation, May 10, 2005; 111(18): 2313 - 2318. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A Doust, E. Pietrzak, A. Dobson, and P. Glasziou How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review BMJ, March 19, 2005; 330(7492): 625. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Schnabel, H. J. Rupprecht, K. J. Lackner, E. Lubos, C. Bickel, J. Meyer, T. Munzel, F. Cambien, L. Tiret, S. Blankenberg, et al. Analysis of N-terminal-pro-brain natriuretic peptide and C-reactive protein for risk stratification in stable and unstable coronary artery disease: results from the AtheroGene study Eur. Heart J., February 1, 2005; 26(3): 241 - 249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Corra, A. Mezzani, E. Bosimini, and P. Giannuzzi Cardiopulmonary Exercise Testing and Prognosis in Chronic Heart Failure*: A Prognosticating Algorithm for the Individual Patient Chest, September 1, 2004; 126(3): 942 - 950. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. V. Milani, C. J. Lavie, and M. R. Mehra Cardiopulmonary Exercise Testing: How Do We Differentiate the Cause of Dyspnea? Circulation, July 27, 2004; 110(4): e27 - e31. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Tandon, F. A. McAlister, R. T. Tsuyuki, M. Hervas-Malo, R. Dupuit, J. Ezekowitz, B. Cujec, and P. W. Armstrong The Use of {beta}-Blockers in a Tertiary Care Heart Failure Clinic: Dosing, Tolerance, and Outcomes Arch Intern Med, April 12, 2004; 164(7): 769 - 774. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Butler, G. Khadim, K. M. Paul, S. F. Davis, M. W. Kronenberg, D. B. Chomsky, R. N. Pierson III, and J. R. Wilson Selection of patients for heart transplantationin the current era of heart failure therapy J. Am. Coll. Cardiol., March 3, 2004; 43(5): 787 - 793. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. de Denus, C. Pharand, and D. R. Williamson Brain Natriuretic Peptide in the Management of Heart Failure: The Versatile Neurohormone Chest, February 1, 2004; 125(2): 652 - 668. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.R Cowie, P Jourdain, A Maisel, U Dahlstrom, F Follath, R Isnard, A Luchner, T McDonagh, J Mair, M Nieminen, et al. Clinical applications of B-type natriuretic peptide (BNP) testing Eur. Heart J., October 1, 2003; 24(19): 1710 - 1718. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R.S. Gardner, F. Ozalp, A.J. Murday, S.D. Robb, and T.A. McDonagh N-terminal pro-brain natriuretic peptide: A new gold standard in predicting mortality in patients with advanced heart failure Eur. Heart J., October 1, 2003; 24(19): 1735 - 1743. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Rickli, W. Kiowski, M. Brehm, D. Weilenmann, C. Schalcher, A. Bernheim, E. Oechslin, and H. P. Brunner-La Rocca Combining low-intensity and maximal exercise test results improves prognostic prediction in chronic heart failure J. Am. Coll. Cardiol., July 2, 2003; 42(1): 116 - 122. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Bittner Exercise testing in heart failure: Maximal, submaximal, or both? J. Am. Coll. Cardiol., July 2, 2003; 42(1): 123 - 125. [Full Text] [PDF]
|
|
|
|
|
|
M. T. La Rovere, G. D. Pinna, R. Maestri, A. Mortara, S. Capomolla, O. Febo, R. Ferrari, M. Franchini, M. Gnemmi, C. Opasich, et al. Short-Term Heart Rate Variability Strongly Predicts Sudden Cardiac Death in Chronic Heart Failure Patients Circulation, February 4, 2003; 107(4): 565 - 570. [Abstract] [Full Text] [PDF]
|
|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
